Renal outcomes according to renal replacement therapy modality and treatment protocol in the ATN and RENAL trials.
Acute kidney injury
Continuous renal replacement therapy
Dialysis dependence
Intermittent hemodialysis
Mortality
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
received:
06
07
2022
accepted:
30
08
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
In critically ill patients with acute kidney injury, renal replacement therapy (RRT) modality and treatment protocols may affect kidney recovery. This study explored whether RRT modality and treatment protocol affected RRT dependence in the 'Randomized Evaluation of Normal versus Augmented Level of RRT' and the 'Acute Renal Failure Trial Network' (ATN) trials. Primary outcome was 28-day RRT dependence. Secondary outcomes included RRT dependence among survivors and in different SOFA-based treatment protocol groups. We used the Fine-Gray competing-risk model sub-distribution hazard ratio (SHR) to assess the primary outcome. Analyses were adjusted for confounders. Of 2542 patients, 2175 (85.5%) received continuous RRT (CRRT) and 367 (14.4%) received intermittent hemodialysis (IHD) as first RRT modality. CRRT-first patients had greater illness severity. After adjustment, there was no between-group difference in 28-day RRT dependence (SHR, 0.96 [95% CI 0.84-1.10]; p = 0.570) or hospital mortality (odds ratio [OR], 1.14 [95% CI 0.86-1.52]; p = 0.361) However, among survivors, CRRT-first was associated with decreased 28-day RRT dependence (OR, 0.54 [95% CI 0.37-0.80]; p = 0.002) and more RRT-free days (common OR: 1.38 [95% CI 1.11-1.71]). Moreover, among CRRT-first patient, the ATN treatment protocol was associated with fewer RRT-free days, greater mortality, and a fourfold increase in RRT dependence at day 28. There was no difference in RRT dependence at day 28 between IHD and CRRT. However, among survivors and after adjustment, both IHD-first and the ATN treatment protocol were strongly associated with greater risk of RRT dependence at 28 days after randomization. Trial registration NCT00221013 registered September 22, 2005, and NCT00076219 registered January 19, 2004.
Sections du résumé
BACKGROUND
In critically ill patients with acute kidney injury, renal replacement therapy (RRT) modality and treatment protocols may affect kidney recovery. This study explored whether RRT modality and treatment protocol affected RRT dependence in the 'Randomized Evaluation of Normal versus Augmented Level of RRT' and the 'Acute Renal Failure Trial Network' (ATN) trials.
METHODS
Primary outcome was 28-day RRT dependence. Secondary outcomes included RRT dependence among survivors and in different SOFA-based treatment protocol groups. We used the Fine-Gray competing-risk model sub-distribution hazard ratio (SHR) to assess the primary outcome. Analyses were adjusted for confounders.
RESULTS
Of 2542 patients, 2175 (85.5%) received continuous RRT (CRRT) and 367 (14.4%) received intermittent hemodialysis (IHD) as first RRT modality. CRRT-first patients had greater illness severity. After adjustment, there was no between-group difference in 28-day RRT dependence (SHR, 0.96 [95% CI 0.84-1.10]; p = 0.570) or hospital mortality (odds ratio [OR], 1.14 [95% CI 0.86-1.52]; p = 0.361) However, among survivors, CRRT-first was associated with decreased 28-day RRT dependence (OR, 0.54 [95% CI 0.37-0.80]; p = 0.002) and more RRT-free days (common OR: 1.38 [95% CI 1.11-1.71]). Moreover, among CRRT-first patient, the ATN treatment protocol was associated with fewer RRT-free days, greater mortality, and a fourfold increase in RRT dependence at day 28.
CONCLUSIONS
There was no difference in RRT dependence at day 28 between IHD and CRRT. However, among survivors and after adjustment, both IHD-first and the ATN treatment protocol were strongly associated with greater risk of RRT dependence at 28 days after randomization. Trial registration NCT00221013 registered September 22, 2005, and NCT00076219 registered January 19, 2004.
Identifiants
pubmed: 36068554
doi: 10.1186/s13054-022-04151-5
pii: 10.1186/s13054-022-04151-5
pmc: PMC9450407
doi:
Banques de données
ClinicalTrials.gov
['NCT00221013', 'NCT00076219', 'NCT00221013']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Informations de copyright
© 2022. The Author(s).
Références
Am J Epidemiol. 2006 Feb 1;163(3):262-70
pubmed: 16371515
N Engl J Med. 2008 Jul 3;359(1):7-20
pubmed: 18492867
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Crit Care Explor. 2021 May 12;3(5):e0399
pubmed: 34079944
N Engl J Med. 2016 Jul 14;375(2):122-33
pubmed: 27181456
Cardiovasc Surg. 2002 Oct;10(5):445-51
pubmed: 12379401
J Crit Care. 2013 Oct;28(5):885.e1-8
pubmed: 23566728
Nephrol Dial Transplant. 2015 Jan;30(1):54-61
pubmed: 25326472
Crit Care. 2022 Apr 4;26(1):93
pubmed: 35379300
Intensive Care Med. 2013 Jun;39(6):987-97
pubmed: 23443311
Clin J Am Soc Nephrol. 2010 Aug;5(8):1366-72
pubmed: 20507953
N Engl J Med. 2009 Oct 22;361(17):1627-38
pubmed: 19846848
N Engl J Med. 2018 Oct 11;379(15):1431-1442
pubmed: 30304656
Nephrol Dial Transplant. 2009 Feb;24(2):512-8
pubmed: 18854418
N Engl J Med. 2020 Jul 16;383(3):240-251
pubmed: 32668114
Kidney Int Rep. 2017 Dec 06;3(2):456-463
pubmed: 29725650
Lancet. 2006 Jul 29;368(9533):379-85
pubmed: 16876666